Drug analysis: TS-1 - Product Image

Drug analysis: TS-1

  • ID: 4462197
  • Drug Pipelines
  • 22 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients. TS-1 inhibits DNA replication, a process that is crucial for cell proliferation and tumor growth. Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is an irreversible inhibitor of thymidylate synthase, an enzyme that is essential for DNA replication. Gimeracil enhances the anti-tumor effects of 5-FU by preventing its degradation within cells. Oteracil potassium reduces the serious gastrointestinal (GI) toxicity caused by 5-FU by inhibiting the phosphorylation of 5-FU in the GI tract.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
TS-1: Colorectal cancer (CRC)
TS-1: Pancreatic cancer

List of Figures
Figure 1: TS-1 for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of TS-1 in colorectal cancer
Figure 3: Drug assessment summary of TS-1 in colorectal cancer
Figure 4: TS-1 sales for colorectal cancer in Japan, 2016-25
Figure 5: TS-1 for pancreatic cancer - SWOT analysis
Figure 6: Drug assessment summary of TS-1 in pancreatic cancer
Figure 7: Drug assessment summary of TS-1 in pancreatic cancer

List of Tables
Table 1: TS-1 drug profile
Table 2: TS-1 pivotal trial data in colorectal cancer
Table 3: TS-1 sales for colorectal cancer in Japan ($m), 2016-25
Table 4: Patients treated with TS-1 in Japan, 2016-25
Table 5: TS-1 drug profile
Table 6: TS-1 pivotal trial data in pancreatic cancer
Table 7: TS-1 other clinical trial data in pancreatic cancer
Table 8: TS-1 ongoing clinical trials in pancreatic cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll